Exubrion Therapeutics® Leadership—
The Exubrion Therapeutics® Team
A seasoned team of managers and directors
Our leadership team brings a broad range of experience in various disciplines, including animal health and nuclear medicine
Martin P. Manco, BS, MBA, JD
Chief Financial Officer | General Counsel
Martin (“Marty”) managed the legal aspects of founding Exubrion. Along with the Chief Veterinary Officer, he was involved in the business aspects of the canine clinical trial program and managed the financial and legal affairs of the company and Serene LLC, its parent.
Marty has a BS in Economics from The Wharton School of the University of Pennsylvania, an MBA from The Pennsylvania State University, and a JD from Widener University School of Law.
In addition, Marty is licensed to practice law in and has a Post-Masters Certificate in Management Information.
“Relieving the pain and suffering of family pets contributes to the quality of life of the entire family. This gives me great pleasure and satisfaction.”
Nigel Stevenson, BSc, PhD
Chief Operating Officer
Nigel works as the operations lead at Exubrion and brings a long history in physics, nuclear physics, and radioisotope research and development to the role. Nigel has held senior positions in several radioisotope manufacturing and research companies in addition to academic roles at National Laboratories. He has over 90 publications and more than 30 patents in this field. He is the Immediate Past President of the World Council on Isotopes.
Nigel holds a BSc in physics and a PhD in nuclear physics from The University of London, U.K.
Nigel is the pet parent of Zoe and Angel, both Pomeranians, his most recent of many beloved dogs.
“As a lifelong dog parent, I sympathize with dogs that suffer from painful conditions and strongly desire to provide a solution that alleviates this.”
Bob Menardi, DVM
Chief Veterinary Officer
Robert Menardi DVM, is Chief Veterinary Officer with Exubrion Therapeutics. He leads the company’s comprehensive veterinary technical education and outreach programs, and serves as the subject matter expert for members of the veterinary profession. He frequently consults with clinical and academic veterinarians on the use of radiosynoviorthesis for treatment of osteoarthritis. He also heads the adverse event reporting and pharmacovigilance functions at Exubrion Therapeutics.
Dr. Menardi worked in private clinical practice for 12 years after graduating from Colorado State University in 1990 with his DVM degree. Prior to joining Exubrion, Dr. Menardi served in multiple leadership roles in the animal health industry. Since 2002, his areas of responsibility have included technical marketing, field veterinary services, veterinary operations and professional development, biologics marketing, and pharmacovigilance.
Eric Schreiber, BSBA
Chief Commercial Officer
Eric heads up marketing, advertising, and sales at Exubrion, bringing 30 years of experience in these disciplines to the team.
He holds a BS in Business Administration from Bucknell University and has completed executive education programs at Wharton and Kellogg.
Eric is the pet parent of Xander, an English Labrador retriever.
“I thrive on the excitement of bringing new technologies to market and seeing their effect on improving the quality of life for pets, pet parents, and veterinarians.”
Anita Jarrard, BS
Director of Administration
Anita leads the organizational functions at Exubrion and brings over 25 years of executive administration experience to the team. Prior to joining Exubrion, she spent 23 years in the big data industry working with top executives at Equifax and LexisNexis.
She holds a BS in business management from the University of Georgia.
Anita is the pet parent of a 6-lb. teacup Yorkie named Trixie, whom she is happy to let rule the home.
“My father instilled the words of Arthur Schopenhauer in my heart: ‘Compassion for animals is intimately associated with goodness of character, and it may be confidently asserted that he who is cruel to animals cannot be a good man.’”
Timothy Corbin
Production Manager
Tim works as the production manager for Exubrion Therapeutics and brings over 25 years of manufacturing experience in the medical device and pharmaceutical industries to the team.
Tim holds a BS in Biochemistry and Chemistry from the University of Georgia.
Tim is the pet parent to 2 dogs: Hank and Dolly, litter mates that are a Chihuahua mix, as well as a cat: Kixie, a yellow tabby.
“I was taught at an early age that my pets' welfare came first. If I was hungry and thirsty, I fed and watered my pets before I ate or drank. It excites me to know that we are providing pain relief to animals that do not understand their pain.”
Synovetin OA® delivers sustained OA pain relief.1
Synovetin OA® provides targeted, non-systemic therapy.2
References:
- Data on file, Exubrion Therapeutics®.
- Donecker JM, Fox SM. Safety and effectiveness of Synovetin OA®: Results of three randomized trials evaluating treatment of naturally occurring canine elbow osteoarthritis. Exubrion Therapeutics®, July 2019.